Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis

Article Dermatology

Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings

Andrew Blauvelt et al.

Summary: In plaque psoriasis patients, ixekizumab treatment showed better persistence, adherence, and lower risk of discontinuation compared to secukinumab in a real-world setting.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis A Study From the British Association of Dermatologists Biologics and Immunomodulators Register

Zenas Z. N. Yiu et al.

Summary: This study compares real-world data with clinical trial data to evaluate the effectiveness of different treatments for psoriasis. The results show that Secukinumab is more effective than Ustekinumab in treating psoriasis in everyday clinical practice, and using a target trial emulation approach can provide robust estimates of relative effectiveness that align with trial data.

JAMA DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Tiago Torres et al.

Summary: In this study, drug survival analysis of the most recent biologic agents approved for the treatment of psoriasis was conducted. Factors such as female sex, higher BMI, and prior exposure to biologic agents were found to significantly increase the risk of drug discontinuation. The study also showed that the drug survival of guselkumab and risankizumab was higher than that of ustekinumab, while secukinumab had a lower drug survival rate.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase

Zenas Z. N. Yiu et al.

Summary: A stratified medicine approach for psoriasis treatment aims to improve clinical decision-making by predicting individual patient response based on clinical, pharmacological, and omics data. The PSORT Consortium, funded by the UK Medical Research Council, focuses on discovering predictors and stratifiers of psoriasis response to biologic therapies. A showcase meeting in London in November 2019 highlighted the research findings and significant advances made by PSORT towards personalized management of psoriasis.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis

Rosa Andres-Ejarque et al.

Summary: By conducting in-depth immunomonitoring of blood immune cells in patients with psoriasis, researchers have identified phosphorylation of NF kappa Bp65 in cDC2 before therapy as an indication of non-response to the anti-TNF therapy adalimumab.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Medicine, General & Internal

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)

Emilie Sbidian et al.

Summary: Psoriasis is an immune-mediated disease with genetic predisposition. Though there is no cure, various treatments can control symptoms. This study compared treatment efficacy and safety using network meta-analysis, finding biologics more effective for achieving PASI 90.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)

添加到收藏夹

Review Dermatology